Tegoprazan: A Next-Generation P-CAB Redefining Acid Suppression
Abstract
Tegoprazan is a novel, potent, and highly selective potassium-competitive acid blocker that inhibits gastric and secretion with rapid onset of action and prolonged control of gastric acidity. In patients with gastroesophageal reflux disease (GERD)whose symptoms improve with acid-suppression therapy, on-demand treatment could constitute maintenance therapy. Potassium-competitive acid blockers and proton pump inhibitors/sodium bicarbonate can rapidly increase intragastric pH. A novel and varied class of medications known as potassium-competitive acid blockers (P-CABs), like tegoprazan, can totally block the potassium-binding site of gastric H+/K+ ATPase, potentially getting around the restrictions of proton-pump inhibitors (PPIs). This mechanism allows for consistent acid suppression across a wide pH range and minimizes variability due to CYP2C19 polymorphisms or food intake. Clinical trials have demonstrated tegoprazan’s efficacy in managing gastroesophageal reflux disease (GERD), peptic ulcers, and Helicobacter pylori infection. It achieves rapid symptoms relief and high healing rates, with a favorable safety profile and minimal adverse effects. Pharmacokinetic reveal a peak plasma concentration within 1-2hours and a half-life of approximately 7-10hours, supporting once-daily dosing. Pharmacodynamic data confirm sustained intragastric pH elevation, even during night time periods. This review consolidates current evidence on tegoprazan’s pharmacology, clinical applications,…
Read the paper
Related studies
- Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2018
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
- Occupation and risk of severe COVID-19: prospective cohort study of 120,075 UK Biobank participants
- Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study
- Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.